New Data on Transcatheter Mitral Valve Repair

Transcatheter repair was associated with less heart failure hospitalization than medical therapy alone in one randomized trial — and was noninferior to surgery in another trial.

Prior studies of transcatheter edge-to-edge repair (TEER) for functional mitral regurgitation (FMR) yielded conflicting results, compared with guideline-directed medical therapy alone: TEER showed no advantage in MITRA-FR (NEJM JW Cardiol Aug 27 2018 and N Engl J Med 2018; 379:2297) but a reduction in heart failure (HF) or death in COAPT (NEJM JW Cardiol Mar 8 2021 and J Am Coll Cardiol 2021; 77:1029). Two manufacturer-funded randomized trials, the multinational RESHAPE-HF2 (NCT02444338 and the MATTERHORN (NCT02371512) from Germany, offer more insight.

RESHAPE-HF2 involved 505 patients (mean age, 70 years; 20% women; median left-ventricular ejection fraction [LVEF], 31%) with symptomatic HF and moderate-to-severe FMR for whom isolated mitral…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)